Corcept Therapeutics Incorporated's Stock Upgrade and Clinical Trial Success

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is focused on developing medications that modulate cortisol effects to treat severe disorders, including oncologic conditions [1] - H.C. Wainwright upgraded CORT's stock to "Buy" and raised its price target from $90 to $105, with the stock priced at approximately $41.87 at the time of the announcement [1][5] Stock Performance - Following the upgrade, CORT's stock has seen a notable increase, currently priced at $41.30, reflecting a 13.74% increase with a change of $4.99 [3][5] - The stock has fluctuated between a low of $40.46 and a high of $52.84 during today's trading [3] - Over the past year, the stock reached a high of $117.33 and a low of $32.99 [3] Clinical Trial Results - The upgrade coincides with significant developments, particularly the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [2] - The trial demonstrated a 35% reduction in the risk of death for patients receiving the combination therapy [2][5] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization and Trading Volume - Corcept's market capitalization is approximately $4.34 billion, with a trading volume of 5,304,058 shares [4]